Nivolumab–relatlimab can be offered as first-line treatment but EMA approval is only for patients with tumour cell PD-L1 expression <1% [I, B; ESMO-MCBS v1.1 score: 3; EMA approved for PD-L1 expression <1%, FDA approval is regardless of PD-L1 expression]. Here, CD274 is linked to neoplasm.